BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Provenge sipuleucel-T regulatory update

CMS issued a proposed decision memo supporting coverage of Dendreon's Provenge for its FDA-approved indication. CMS said there is adequate evidence to conclude that the autologous cellular immunotherapy improves health outcomes in patients with metastatic, castration-resistant prostate cancer (CRPC)...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >